Esophageal carcinoma: Towards targeted therapies

go back to reference J. Lagergren, E. Smyth, D. Cunningham, P. Lagergren, Oesophageal cancer. Lancet 390, 2383–2396 (2017)CrossRefPubMed J. Lagergren, E. Smyth, D. Cunningham, P. Lagergren, Oesophageal cancer. Lancet 390, 2383–2396 (2017)CrossRefPubMed

go back to reference Cancer Genome Atlas Research Network; Analysis Working Group: Asan University; BC Cancer Agency; Brigham and Women’s Hospital; Broad Institute; Brown University; Case Western Reserve University; Dana-Farber Cancer Institute; Duke University; Greater Poland Cancer Centre; Harvard Medical School; Institute for Systems Biology; KU Leuven; Mayo Clinic; Memorial Sloan Kettering Cancer Center; National Cancer Institute; Nationwide Children’s Hospital; Stanford University; University of Alabama; University of Michigan; University of North Carolina; University of Pittsburgh; University of Rochester; University of Southern California; University of Texas MD Anderson Cancer Center; University of Washington; Van Andel Research Institute; Vanderbilt University; Washington University; Genome Sequencing Center: Broad Institute; Washington University in St. Louis; Genome Characterization Centers: BC Cancer Agency; Broad Institute; Harvard Medical School; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University; University of North Carolina; University of Southern California Epigenome Center; University of Texas MD Anderson Cancer Center; Van Andel Research Institute; Genome Data Analysis Centers: Broad Institute; Brown University:; Harvard Medical School; Institute for Systems Biology; Memorial Sloan Kettering Cancer Center; University of California Santa Cruz; University of Texas MD Anderson Cancer Center; Biospecimen Core Resource: International Genomics Consortium; Research Institute at Nationwide Children’s Hospital; Tissue Source Sites: Analytic Biologic Services; Asan Medical Center; Asterand Bioscience; Barretos Cancer Hospital; BioreclamationIVT; Botkin Municipal Clinic; Chonnam National University Medical School; Christiana Care Health System; Cureline; Duke University; Emory University; Erasmus University; Indiana University School of Medicine; Institute of Oncology of Moldova; International Genomics Consortium; Invidumed; Israelitisches Krankenhaus Hamburg; Keimyung University School of Medicine; Memorial Sloan Kettering Cancer Center; National Cancer Center Goyang; Ontario Tumour Bank; Peter MacCallum Cancer Centre; Pusan National University Medical School; Ribeirão Preto Medical School; St. Joseph’s Hospital &Medical Center; St. Petersburg Academic University; Tayside Tissue Bank; University of Dundee; University of Kansas Medical Center; University of Michigan; University of North Carolina at Chapel Hill; University of Pittsburgh School of Medicine; University of Texas MD Anderson Cancer Center; Disease Working Group: Duke University; Memorial Sloan Kettering Cancer Center; National Cancer Institute; University of Texas MD Anderson Cancer Center; Yonsei University College of Medicine; Data Coordination Center: CSRA Inc.; Project Team: National Institutes of Health, Integrated genomic characterization of oesophageal carcinoma. Nature 541, 169–175 (2017)CrossRef Cancer Genome Atlas Research Network; Analysis Working Group: Asan University; BC Cancer Agency; Brigham and Women’s Hospital; Broad Institute; Brown University; Case Western Reserve University; Dana-Farber Cancer Institute; Duke University; Greater Poland Cancer Centre; Harvard Medical School; Institute for Systems Biology; KU Leuven; Mayo Clinic; Memorial Sloan Kettering Cancer Center; National Cancer Institute; Nationwide Children’s Hospital; Stanford University; University of Alabama; University of Michigan; University of North Carolina; University of Pittsburgh; University of Rochester; University of Southern California; University of Texas MD Anderson Cancer Center; University of Washington; Van Andel Research Institute; Vanderbilt University; Washington University; Genome Sequencing Center: Broad Institute; Washington University in St. Louis; Genome Characterization Centers: BC Cancer Agency; Broad Institute; Harvard Medical School; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University; University of North Carolina; University of Southern California Epigenome Center; University of Texas MD Anderson Cancer Center; Van Andel Research Institute; Genome Data Analysis Centers: Broad Institute; Brown University:; Harvard Medical School; Institute for Systems Biology; Memorial Sloan Kettering Cancer Center; University of California Santa Cruz; University of Texas MD Anderson Cancer Center; Biospecimen Core Resource: International Genomics Consortium; Research Institute at Nationwide Children’s Hospital; Tissue Source Sites: Analytic Biologic Services; Asan Medical Center; Asterand Bioscience; Barretos Cancer Hospital; BioreclamationIVT; Botkin Municipal Clinic; Chonnam National University Medical School; Christiana Care Health System; Cureline; Duke University; Emory University; Erasmus University; Indiana University School of Medicine; Institute of Oncology of Moldova; International Genomics Consortium; Invidumed; Israelitisches Krankenhaus Hamburg; Keimyung University School of Medicine; Memorial Sloan Kettering Cancer Center; National Cancer Center Goyang; Ontario Tumour Bank; Peter MacCallum Cancer Centre; Pusan National University Medical School; Ribeirão Preto Medical School; St. Joseph’s Hospital &Medical Center; St. Petersburg Academic University; Tayside Tissue Bank; University of Dundee; University of Kansas Medical Center; University of Michigan; University of North Carolina at Chapel Hill; University of Pittsburgh School of Medicine; University of Texas MD Anderson Cancer Center; Disease Working Group: Duke University; Memorial Sloan Kettering Cancer Center; National Cancer Institute; University of Texas MD Anderson Cancer Center; Yonsei University College of Medicine; Data Coordination Center: CSRA Inc.; Project Team: National Institutes of Health, Integrated genomic characterization of oesophageal carcinoma. Nature 541, 169–175 (2017)CrossRef

go back to reference Y.B. Gao, Z.L. Chen, J.G. Li, X.D. Hu, X.J. Shi, Z.M. Sun, F. Zhang, Z.R. Zhao, Z.T. Li, Z.Y. Liu, Y.D. Zhao, J. Sun, C.C. Zhou, R. Yao, S.Y. Wang, P. Wang, N. Sun, B.H. Zhang, J.S. Dong, Y. Yu, M. Luo, X.L. Feng, S.S. Shi, F. Zhou, F.W. Tan, B. Qiu, N. Li, K. Shao, L.J. Zhang, Q. Xue, S.G. Gao, J. He, Genetic landscape of esophageal squamous cell carcinoma. Nat Genet 46, 1097–1102 (2014) Y.B. Gao, Z.L. Chen, J.G. Li, X.D. Hu, X.J. Shi, Z.M. Sun, F. Zhang, Z.R. Zhao, Z.T. Li, Z.Y. Liu, Y.D. Zhao, J. Sun, C.C. Zhou, R. Yao, S.Y. Wang, P. Wang, N. Sun, B.H. Zhang, J.S. Dong, Y. Yu, M. Luo, X.L. Feng, S.S. Shi, F. Zhou, F.W. Tan, B. Qiu, N. Li, K. Shao, L.J. Zhang, Q. Xue, S.G. Gao, J. He, Genetic landscape of esophageal squamous cell carcinoma. Nat Genet 46, 1097–1102 (2014)

go back to reference D.C. Lin, J.J. Hao, Y. Nagata, L. Xu, L. Shang, X. Meng, Y. Sato, Y. Okuno, A.M. Varela, L.W. Ding, M. Garg, L.Z. Liu, H. Yang, D. Yin, Z.Z. Shi, Y.Y. Jiang, W.Y. Gu, T. Gong, Y. Zhang, X. Xu, O. Kalid, S. Shacham, S. Ogawa, M.R. Wang, H.P. Koeffler, Genomic and molecular characterization of esophageal squamous cell carcinoma. Nat Genet 46, 467–473 (2014)CrossRefPubMedPubMedCentral D.C. Lin, J.J. Hao, Y. Nagata, L. Xu, L. Shang, X. Meng, Y. Sato, Y. Okuno, A.M. Varela, L.W. Ding, M. Garg, L.Z. Liu, H. Yang, D. Yin, Z.Z. Shi, Y.Y. Jiang, W.Y. Gu, T. Gong, Y. Zhang, X. Xu, O. Kalid, S. Shacham, S. Ogawa, M.R. Wang, H.P. Koeffler, Genomic and molecular characterization of esophageal squamous cell carcinoma. Nat Genet 46, 467–473 (2014)CrossRefPubMedPubMedCentral

go back to reference C.C. Abnet, M. Arnold, W.Q. Wei, Epidemiology of esophageal squamous cell carcinoma. Gastroenterology 154, 360–373 (2018)CrossRefPubMed C.C. Abnet, M. Arnold, W.Q. Wei, Epidemiology of esophageal squamous cell carcinoma. Gastroenterology 154, 360–373 (2018)CrossRefPubMed

go back to reference E.C. Smyth, J. Lagergren, R.C. Fitzgerald, F. Lordick, M.A. Shah, P. Lagergren, D. Cunningham, Oesophageal cancer. Nat Rev Dis Primers 3, 17048 (2017)CrossRefPubMedPubMedCentral E.C. Smyth, J. Lagergren, R.C. Fitzgerald, F. Lordick, M.A. Shah, P. Lagergren, D. Cunningham, Oesophageal cancer. Nat Rev Dis Primers 3, 17048 (2017)CrossRefPubMedPubMedCentral

go back to reference J. Rüdiger Siewert, M. Feith, M. Werner, H.J. Stein, Adenocarcinoma of the esophagogastric junction: Results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg 232, 353–361 (2000) J. Rüdiger Siewert, M. Feith, M. Werner, H.J. Stein, Adenocarcinoma of the esophagogastric junction: Results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg 232, 353–361 (2000)

go back to reference F.L. Huang, S.J. Yu, Esophageal cancer: Risk factors, genetic association, and treatment. Asian J Surg 41, 210–215 (2018)CrossRefPubMed F.L. Huang, S.J. Yu, Esophageal cancer: Risk factors, genetic association, and treatment. Asian J Surg 41, 210–215 (2018)CrossRefPubMed

go back to reference M.Q. Lin, Y.P. Li, S.G. Wu, J.Y. Sun, H.X. Lin, S.Y. Zhang, Z.Y. He, Differences in esophageal cancer characteristics and survival between Chinese and Caucasian patients in the SEER database. Onco Targets Ther 9, 6435–6444 (2016)CrossRefPubMedPubMedCentral M.Q. Lin, Y.P. Li, S.G. Wu, J.Y. Sun, H.X. Lin, S.Y. Zhang, Z.Y. He, Differences in esophageal cancer characteristics and survival between Chinese and Caucasian patients in the SEER database. Onco Targets Ther 9, 6435–6444 (2016)CrossRefPubMedPubMedCentral

go back to reference Y. Kitagawa, T. Uno, T. Oyama, K. Kato, H. Kato, H. Kawakubo, O. Kawamura, M. Kusano, H. Kuwano, H. Takeuchi, Y. Toh, Y. Doki, Y. Naomoto, K. Nemoto, E. Booka, H. Matsubara, T. Miyazaki, M. Muto, A. Yanagisawa, M. Yoshida, Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: Part 2. Esophagus 16, 25–43 (2019)CrossRefPubMed Y. Kitagawa, T. Uno, T. Oyama, K. Kato, H. Kato, H. Kawakubo, O. Kawamura, M. Kusano, H. Kuwano, H. Takeuchi, Y. Toh, Y. Doki, Y. Naomoto, K. Nemoto, E. Booka, H. Matsubara, T. Miyazaki, M. Muto, A. Yanagisawa, M. Yoshida, Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: Part 2. Esophagus 16, 25–43 (2019)CrossRefPubMed

go back to reference F. Lordick, C. Mariette, K. Haustermans, R. Obermannová, D. Arnold, E.G. Committee, Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 27(suppl 5), v50–v57 (2016)CrossRefPubMed F. Lordick, C. Mariette, K. Haustermans, R. Obermannová, D. Arnold, E.G. Committee, Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 27(suppl 5), v50–v57 (2016)CrossRefPubMed

go back to reference J.A. Ajani, T.A. D’Amico, D.J. Bentrem, J. Chao, C. Corvera, P. Das, C.S. Denlinger, P.C. Enzinger, P. Fanta, F. Farjah, H. Gerdes, M. Gibson, R.E. Glasgow, J.A. Hayman, S. Hochwald, W.L. Hofstetter, D.H. Ilson, D. Jaroszewski, K.L. Johung, R.N. Keswani, L.R. Kleinberg, S. Leong, Q.P. Ly, K.A. Matkowskyj, M. McNamara, M.F. Mulcahy, R.K. Paluri, H. Park, K.A. Perry, J. Pimiento, G.A. Poultsides, R. Roses, V.E. Strong, G. Wiesner, C.G. Willett, C.D. Wright, N.R. McMillian, L.A. Pluchino, Esophageal and esophagogastric junction cancers. J Natl Compr Cancer Netw 17(7), 855–883 (2019) J.A. Ajani, T.A. D’Amico, D.J. Bentrem, J. Chao, C. Corvera, P. Das, C.S. Denlinger, P.C. Enzinger, P. Fanta, F. Farjah, H. Gerdes, M. Gibson, R.E. Glasgow, J.A. Hayman, S. Hochwald, W.L. Hofstetter, D.H. Ilson, D. Jaroszewski, K.L. Johung, R.N. Keswani, L.R. Kleinberg, S. Leong, Q.P. Ly, K.A. Matkowskyj, M. McNamara, M.F. Mulcahy, R.K. Paluri, H. Park, K.A. Perry, J. Pimiento, G.A. Poultsides, R. Roses, V.E. Strong, G. Wiesner, C.G. Willett, C.D. Wright, N.R. McMillian, L.A. Pluchino, Esophageal and esophagogastric junction cancers. J Natl Compr Cancer Netw 17(7), 855–883 (2019)

go back to reference T.W. Rice, D.T. Patil, E.H. Blackstone, 8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric junction: Application to clinical practice. Ann Cardiothorac Surg 6, 119–130 (2017)CrossRefPubMedPubMedCentral T.W. Rice, D.T. Patil, E.H. Blackstone, 8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric junction: Application to clinical practice. Ann Cardiothorac Surg 6, 119–130 (2017)CrossRefPubMedPubMedCentral

go back to reference T.N. Walsh, N. Noonan, D. Hollywood, A. Kelly, N. Keeling, T.P. Hennessy, A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 335, 462–467 (1996)CrossRefPubMed T.N. Walsh, N. Noonan, D. Hollywood, A. Kelly, N. Keeling, T.P. Hennessy, A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 335, 462–467 (1996)CrossRefPubMed

go back to reference V. Gebski, B. Burmeister, B.M. Smithers, K. Foo, J. Zalcberg, J. Simes, Australasian Gastro-Intestinal Trials Group, Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: A meta-analysis. Lancet Oncol 8, 226–234 (2007)CrossRefPubMed V. Gebski, B. Burmeister, B.M. Smithers, K. Foo, J. Zalcberg, J. Simes, Australasian Gastro-Intestinal Trials Group, Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: A meta-analysis. Lancet Oncol 8, 226–234 (2007)CrossRefPubMed

go back to reference J. Shapiro, J.J.B. van Lanschot, M.C.C.M. Hulshof, P. van Hagen, M.I. van Berge Henegouwen, B.P.L. Wijnhoven, H.W.M. van Laarhoven, G.A.P. Nieuwenhuijzen, G.A.P. Hospers, J.J. Bonenkamp, M.A. Cuesta, R.J.B. Blaisse, O.R.C. Busch, F.J.W. Ten Kate, G.M. Creemers, C.J.A. Punt, J.T.M. Plukker, H.M.W. Verheul, E.J.S. Bilgen, H. van Dekken, M.J.C. van der Sangen, T. Rozema, K. Biermann, J.C. Beukema, A.H.M. Piet, C.M. van Rij, J.G. Reinders, H.W. Tilanus, E.W. Steyerberg, A. van der Gaast, CROSS Study Group, Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): Long-term results of a randomised controlled trial. Lancet Oncol 16, 1090–1098 (2015)CrossRefPubMed J. Shapiro, J.J.B. van Lanschot, M.C.C.M. Hulshof, P. van Hagen, M.I. van Berge Henegouwen, B.P.L. Wijnhoven, H.W.M. van Laarhoven, G.A.P. Nieuwenhuijzen, G.A.P. Hospers, J.J. Bonenkamp, M.A. Cuesta, R.J.B. Blaisse, O.R.C. Busch, F.J.W. Ten Kate, G.M. Creemers, C.J.A. Punt, J.T.M. Plukker, H.M.W. Verheul, E.J.S. Bilgen, H. van Dekken, M.J.C. van der Sangen, T. Rozema, K. Biermann, J.C. Beukema, A.H.M. Piet, C.M. van Rij, J.G. Reinders, H.W. Tilanus, E.W. Steyerberg, A. van der Gaast, CROSS Study Group, Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): Long-term results of a randomised controlled trial. Lancet Oncol 16, 1090–1098 (2015)CrossRefPubMed

go back to reference J. Tepper, M.J. Krasna, D. Niedzwiecki, D. Hollis, C.E. Reed, R. Goldberg, K. Kiel, C. Willett, D. Sugarbaker, R. Mayer, Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 26, 1086–1092 (2008)CrossRefPubMed J. Tepper, M.J. Krasna, D. Niedzwiecki, D. Hollis, C.E. Reed, R. Goldberg, K. Kiel, C. Willett, D. Sugarbaker, R. Mayer, Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 26, 1086–1092 (2008)CrossRefPubMed

go back to reference J.S. Cooper, M.D. Guo, A. Herskovic, J.S. Macdonald, J.A. Martenson, M. Al-Sarraf, R. Byhardt, A.H. Russell, J.J. Beitler, S. Spencer, S.O. Asbell, M.V. Graham, L.L. Leichman, Chemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 281, 1623–1627 (1999)CrossRefPubMed J.S. Cooper, M.D. Guo, A. Herskovic, J.S. Macdonald, J.A. Martenson, M. Al-Sarraf, R. Byhardt, A.H. Russell, J.J. Beitler, S. Spencer, S.O. Asbell, M.V. Graham, L.L. Leichman, Chemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 281, 1623–1627 (1999)CrossRefPubMed

go back to reference S. Paul, N. Altorki, Outcomes in the management of esophageal cancer. J Surg Oncol 110, 599–610 (2014)CrossRefPubMed S. Paul, N. Altorki, Outcomes in the management of esophageal cancer. J Surg Oncol 110, 599–610 (2014)CrossRefPubMed

go back to reference J. Chang, W. Tan, Z. Ling, R. Xi, M. Shao, M. Chen, Y. Luo, Y. Zhao, Y. Liu, X. Huang, Y. Xia, J. Hu, J.S. Parker, D. Marron, Q. Cui, L. Peng, J. Chu, H. Li, Z. Du, Y. Han, Z. Liu, Q. Zhan, Y. Li, W. Mao, C. Wu, D. Lin, Genomic analysis of oesophageal squamous-cell carcinoma identifies alcohol drinking-related mutation signature and genomic alterations. Nat Commun 8, 15290 (2017)CrossRefPubMedPubMedCentral J. Chang, W. Tan, Z. Ling, R. Xi, M. Shao, M. Chen, Y. Luo, Y. Zhao, Y. Liu, X. Huang, Y. Xia, J. Hu, J.S. Parker, D. Marron, Q. Cui, L. Peng, J. Chu, H. Li, Z. Du, Y. Han, Z. Liu, Q. Zhan, Y. Li, W. Mao, C. Wu, D. Lin, Genomic analysis of oesophageal squamous-cell carcinoma identifies alcohol drinking-related mutation signature and genomic alterations. Nat Commun 8, 15290 (2017)CrossRefPubMedPubMedCentral

go back to reference C. Cheng, Y. Zhou, H. Li, T. Xiong, S. Li, Y. Bi, P. Kong, F. Wang, H. Cui, Y. Li, X. Fang, T. Yan, J. Wang, B. Yang, L. Zhang, Z. Jia, B. Song, X. Hu, J. Yang, H. Qiu, G. Zhang, J. Liu, E. Xu, R. Shi, Y. Zhang, H. Liu, C. He, Z. Zhao, Y. Qian, R. Rong, Z. Han, W. Luo, S. Peng, X. Yang, X. Li, L. Li, H. Fang, X. Liu, L. Ma, Y. Chen, S. Guo, X. Chen, Y. Xi, G. Li, J. Liang, J. Guo, J. Jia, Q. Li, X. Cheng, Q. Zhan, Y. Cui, Whole-genome sequencing reveals diverse models of structural variations in esophageal squamous cell carcinoma. Am J Hum Genet 98, 256–274 (2016)CrossRefPubMedPubMedCentral C. Cheng, Y. Zhou, H. Li, T. Xiong, S. Li, Y. Bi, P. Kong, F. Wang, H. Cui, Y. Li, X. Fang, T. Yan, J. Wang, B. Yang, L. Zhang, Z. Jia, B. Song, X. Hu, J. Yang, H. Qiu, G. Zhang, J. Liu, E. Xu, R. Shi, Y. Zhang, H. Liu, C. He, Z. Zhao, Y. Qian, R. Rong, Z. Han, W. Luo, S. Peng, X. Yang, X. Li, L. Li, H. Fang, X. Liu, L. Ma, Y. Chen, S. Guo, X. Chen, Y. Xi, G. Li, J. Liang, J. Guo, J. Jia, Q. Li, X. Cheng, Q. Zhan, Y. Cui, Whole-genome sequencing reveals diverse models of structural variations in esophageal squamous cell carcinoma. Am J Hum Genet 98, 256–274 (2016)CrossRefPubMedPubMedCentral

go back to reference J. Deng, H. Chen, D. Zhou, J. Zhang, Y. Chen, Q. Liu, D. Ai, H. Zhu, L. Chu, W. Ren, X. Zhang, Y. Xia, M. Sun, H. Zhang, J. Li, X. Peng, L. Li, L. Han, H. Lin, X. Cai, J. Xiang, S. Chen, Y. Sun, Y. Zhang, S. Zhang, Y. Zhao, Y. Liu, H. Liang, K. Zhao, Comparative genomic analysis of esophageal squamous cell carcinoma between Asian and Caucasian patient populations. Nat Commun 8, 1533 (2017)CrossRefPubMedPubMedCentral J. Deng, H. Chen, D. Zhou, J. Zhang, Y. Chen, Q. Liu, D. Ai, H. Zhu, L. Chu, W. Ren, X. Zhang, Y. Xia, M. Sun, H. Zhang, J. Li, X. Peng, L. Li, L. Han, H. Lin, X. Cai, J. Xiang, S. Chen, Y. Sun, Y. Zhang, S. Zhang, Y. Zhao, Y. Liu, H. Liang, K. Zhao, Comparative genomic analysis of esophageal squamous cell carcinoma between Asian and Caucasian patient populations. Nat Commun 8, 1533 (2017)CrossRefPubMedPubMedCentral

go back to reference J. Deng, X. Weng, J. Ye, D. Zhou, Y. Liu, K. Zhao, Identification of the germline mutation profile in esophageal squamous cell carcinoma by whole exome sequencing. Front Genet 10, 47 (2019)CrossRefPubMedPubMedCentral J. Deng, X. Weng, J. Ye, D. Zhou, Y. Liu, K. Zhao, Identification of the germline mutation profile in esophageal squamous cell carcinoma by whole exome sequencing. Front Genet 10, 47 (2019)CrossRefPubMedPubMedCentral

go back to reference H.D. Qin, X.Y. Liao, Y.B. Chen, S.Y. Huang, W.Q. Xue, F.F. Li, X.S. Ge, D.Q. Liu, Q. Cai, J. Long, X.Z. Li, Y.Z. Hu, S.D. Zhang, L.J. Zhang, B. Lehrman, A.F. Scott, D. Lin, Y.X. Zeng, Y.Y. Shugart, W.H. Jia, Genomic characterization of esophageal squamous cell carcinoma reveals critical genes underlying tumorigenesis and poor prognosis. Am J Hum Genet 98, 709–727 (2016)CrossRefPubMedPubMedCentral H.D. Qin, X.Y. Liao, Y.B. Chen, S.Y. Huang, W.Q. Xue, F.F. Li, X.S. Ge, D.Q. Liu, Q. Cai, J. Long, X.Z. Li, Y.Z. Hu, S.D. Zhang, L.J. Zhang, B. Lehrman, A.F. Scott, D. Lin, Y.X. Zeng, Y.Y. Shugart, W.H. Jia, Genomic characterization of esophageal squamous cell carcinoma reveals critical genes underlying tumorigenesis and poor prognosis. Am J Hum Genet 98, 709–727 (2016)CrossRefPubMedPubMedCentral

go back to reference Y. Song, L. Li, Y. Ou, Z. Gao, E. Li, X. Li, W. Zhang, J. Wang, L. Xu, Y. Zhou, X. Ma, L. Liu, Z. Zhao, X. Huang, J. Fan, L. Dong, G. Chen, L. Ma, J. Yang, L. Chen, M. He, M. Li, X. Zhuang, K. Huang, K. Qiu, G. Yin, G. Guo, Q. Feng, P. Chen, Z. Wu, J. Wu, J. Zhao, L. Luo, M. Fu, B. Xu, B. Chen, Y. Li, T. Tong, M. Wang, Z. Liu, D. Lin, X. Zhang, H. Yang, Q. Zhan, Identification of genomic alterations in oesophageal squamous cell cancer. Nature 509, 91–95 (2014)CrossRefPubMed Y. Song, L. Li, Y. Ou, Z. Gao, E. Li, X. Li, W. Zhang, J. Wang, L. Xu, Y. Zhou, X. Ma, L. Liu, Z. Zhao, X. Huang, J. Fan, L. Dong, G. Chen, L. Ma, J. Yang, L. Chen, M. He, M. Li, X. Zhuang, K. Huang, K. Qiu, G. Yin, G. Guo, Q. Feng, P. Chen, Z. Wu, J. Wu, J. Zhao, L. Luo, M. Fu, B. Xu, B. Chen, Y. Li, T. Tong, M. Wang, Z. Liu, D. Lin, X. Zhang, H. Yang, Q. Zhan, Identification of genomic alterations in oesophageal squamous cell cancer. Nature 509, 91–95 (2014)CrossRefPubMed

go back to reference T. Xiong, M. Wang, J. Zhao, Q. Liu, C. Yang, W. Luo, X. Li, H. Yang, K. Kristiansen, B. Roy, Y. Zhou, An esophageal squamous cell carcinoma classification system that reveals potential targets for therapy. Oncotarget 8, 49851–49860 (2017)CrossRefPubMedPubMedCentral T. Xiong, M. Wang, J. Zhao, Q. Liu, C. Yang, W. Luo, X. Li, H. Yang, K. Kristiansen, B. Roy, Y. Zhou, An esophageal squamous cell carcinoma classification system that reveals potential targets for therapy. Oncotarget 8, 49851–49860 (2017)CrossRefPubMedPubMedCentral

go back to reference L. Zhang, Y. Zhou, C. Cheng, H. Cui, L. Cheng, P. Kong, J. Wang, Y. Li, W. Chen, B. Song, F. Wang, Z. Jia, L. Li, B. Yang, J. Liu, R. Shi, Y. Bi, Y. Zhang, Z. Zhao, X. Hu, J. Yang, H. Li, Z. Gao, G. Chen, X. Huang, X. Yang, S. Wan, C. Chen, B. Li, Y. Tan, L. Chen, M. He, S. Xie, X. Li, X. Zhuang, M. Wang, Z. Xia, L. Luo, J. Ma, B. Dong, J. Zhao, Y. Song, Y. Ou, E. Li, L. Xu, Y. Xi, G. Li, E. Xu, J. Liang, J. Guo, X. Chen, Q. Li, L. Liu, X. Zhang, H. Yang, D. Lin, X. Cheng, Y. Guo, Q. Zhan, Y. Cui, Genomic analyses reveal mutational signatures and frequently altered genes in esophageal squamous cell carcinoma. Am J Hum Genet 96, 597–611 (2015)CrossRefPubMedPubMedCentral L. Zhang, Y. Zhou, C. Cheng, H. Cui, L. Cheng, P. Kong, J. Wang, Y. Li, W. Chen, B. Song, F. Wang, Z. Jia, L. Li, B. Yang, J. Liu, R. Shi, Y. Bi, Y. Zhang, Z. Zhao, X. Hu, J. Yang, H. Li, Z. Gao, G. Chen, X. Huang, X. Yang, S. Wan, C. Chen, B. Li, Y. Tan, L. Chen, M. He, S. Xie, X. Li, X. Zhuang, M. Wang, Z. Xia, L. Luo, J. Ma, B. Dong, J. Zhao, Y. Song, Y. Ou, E. Li, L. Xu, Y. Xi, G. Li, E. Xu, J. Liang, J. Guo, X. Chen, Q. Li, L. Liu, X. Zhang, H. Yang, D. Lin, X. Cheng, Y. Guo, Q. Zhan, Y. Cui, Genomic analyses reveal mutational signatures and frequently altered genes in esophageal squamous cell carcinoma. Am J Hum Genet 96, 597–611 (2015)CrossRefPubMedPubMedCentral

go back to reference M. Hazawa, D.C. Lin, H. Handral, L. Xu, Y. Chen, Y.Y. Jiang, A. Mayakonda, L.W. Ding, X. Meng, A. Sharma, S. Samuel, M.M. Movahednia, R.W. Wong, H. Yang, C. Tong, H.P. Koeffler, ZNF750 is a lineage-specific tumour suppressor in squamous cell carcinoma. Oncogene 36, 2243–2254 (2017)CrossRefPubMed M. Hazawa, D.C. Lin, H. Handral, L. Xu, Y. Chen, Y.Y. Jiang, A. Mayakonda, L.W. Ding, X. Meng, A. Sharma, S. Samuel, M.M. Movahednia, R.W. Wong, H. Yang, C. Tong, H.P. Koeffler, ZNF750 is a lineage-specific tumour suppressor in squamous cell carcinoma. Oncogene 36, 2243–2254 (2017)CrossRefPubMed

go back to reference M. Secrier, X. Li, N. de Silva, M.D. Eldridge, G. Contino, J. Bornschein, S. MacRae, N. Grehan, M. O'Donovan, A. Miremadi, T.P. Yang, L. Bower, H. Chettouh, J. Crawte, N. Galeano-Dalmau, A. Grabowska, J. Saunders, T. Underwood, N. Waddell, A.P. Barbour, B. Nutzinger, A. Achilleos, P.A. Edwards, A.G. Lynch, S. Tavaré, R.C. Fitzgerald, Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium, Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. Nat Genet 48, 1131–1141 (2016)CrossRefPubMedPubMedCentral M. Secrier, X. Li, N. de Silva, M.D. Eldridge, G. Contino, J. Bornschein, S. MacRae, N. Grehan, M. O'Donovan, A. Miremadi, T.P. Yang, L. Bower, H. Chettouh, J. Crawte, N. Galeano-Dalmau, A. Grabowska, J. Saunders, T. Underwood, N. Waddell, A.P. Barbour, B. Nutzinger, A. Achilleos, P.A. Edwards, A.G. Lynch, S. Tavaré, R.C. Fitzgerald, Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium, Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. Nat Genet 48, 1131–1141 (2016)CrossRefPubMedPubMedCentral

go back to reference Y.J. Bang, E. Van Cutsem, A. Feyereislova, H.C. Chung, L. Shen, A. Sawaki, F. Lordick, A. Ohtsu, Y. Omuro, T. Satoh, G. Aprile, E. Kulikov, J. Hill, M. Lehle, J. Rüschoff, Y.K. Kang, T.T. Investigators, Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 376, 687–697 (2010)CrossRefPubMed Y.J. Bang, E. Van Cutsem, A. Feyereislova, H.C. Chung, L. Shen, A. Sawaki, F. Lordick, A. Ohtsu, Y. Omuro, T. Satoh, G. Aprile, E. Kulikov, J. Hill, M. Lehle, J. Rüschoff, Y.K. Kang, T.T. Investigators, Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 376, 687–697 (2010)CrossRefPubMed

go back to reference C.S. Fuchs, T. Doi, R.W. Jang, K. Muro, T. Satoh, M. Machado, W. Sun, S.I. Jalal, M.A. Shah, J.P. Metges, M. Garrido, T. Golan, M. Mandala, Z.A. Wainberg, D.V. Catenacci, A. Ohtsu, K. Shitara, R. Geva, J. Bleeker, A.H. Ko, G. Ku, P. Philip, P.C. Enzinger, Y.J. Bang, D. Levitan, J. Wang, M. Rosales, R.P. Dalal, H.H. Yoon, Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: Phase 2 clinical KEYNOTE-059 Trial. JAMA Oncol 4, e180013 (2018)CrossRefPubMedPubMedCentral C.S. Fuchs, T. Doi, R.W. Jang, K. Muro, T. Satoh, M. Machado, W. Sun, S.I. Jalal, M.A. Shah, J.P. Metges, M. Garrido, T. Golan, M. Mandala, Z.A. Wainberg, D.V. Catenacci, A. Ohtsu, K. Shitara, R. Geva, J. Bleeker, A.H. Ko, G. Ku, P. Philip, P.C. Enzinger, Y.J. Bang, D. Levitan, J. Wang, M. Rosales, R.P. Dalal, H.H. Yoon, Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: Phase 2 clinical KEYNOTE-059 Trial. JAMA Oncol 4, e180013 (2018)CrossRefPubMedPubMedCentral

go back to reference C.S. Fuchs, J. Tomasek, C.J. Yong, F. Dumitru, R. Passalacqua, C. Goswami, H. Safran, L.V.D. Santos, G. Aprile, D.R. Ferry, B. Melichar, M. Tehfe, E. Topuzov, J.R. Zalcberg, I. Chau, W. Campbell, C. Sivanandan, J. Pikiel, M. Koshiji, Y. Hsu, A.M. Liepa, L. Gao, J.D. Schwartz, J. Tabernero, R.T. Investigators, Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383, 31–39 (2014)CrossRefPubMed C.S. Fuchs, J. Tomasek, C.J. Yong, F. Dumitru, R. Passalacqua, C. Goswami, H. Safran, L.V.D. Santos, G. Aprile, D.R. Ferry, B. Melichar, M. Tehfe, E. Topuzov, J.R. Zalcberg, I. Chau, W. Campbell, C. Sivanandan, J. Pikiel, M. Koshiji, Y. Hsu, A.M. Liepa, L. Gao, J.D. Schwartz, J. Tabernero, R.T. Investigators, Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383, 31–39 (2014)CrossRefPubMed

go back to reference M.A. Shah, T. Kojima, D. Hochhauser, P. Enzinger, J. Raimbourg, A. Hollebecque, F. Lordick, S.B. Kim, M. Tajika, H.T. Kim, A.C. Lockhart, H.T. Arkenau, F. El-Hajbi, M. Gupta, P. Pfeiffer, Q. Liu, J. Lunceford, S.P. Kang, P. Bhagia, K. Kato, Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: The phase 2 KEYNOTE-180 study. JAMA Oncol 5, 546-550 (2019) M.A. Shah, T. Kojima, D. Hochhauser, P. Enzinger, J. Raimbourg, A. Hollebecque, F. Lordick, S.B. Kim, M. Tajika, H.T. Kim, A.C. Lockhart, H.T. Arkenau, F. El-Hajbi, M. Gupta, P. Pfeiffer, Q. Liu, J. Lunceford, S.P. Kang, P. Bhagia, K. Kato, Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: The phase 2 KEYNOTE-180 study. JAMA Oncol 5, 546-550 (2019)

go back to reference H. Wilke, K. Muro, E. Van Cutsem, S.C. Oh, G. Bodoky, Y. Shimada, S. Hironaka, N. Sugimoto, O. Lipatov, T.Y. Kim, D. Cunningham, P. Rougier, Y. Komatsu, J. Ajani, M. Emig, R. Carlesi, D. Ferry, K. Chandrawansa, J.D. Schwartz, A. Ohtsu, RAINBOW Study Group, Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): A double-blind, randomised phase 3 trial. Lancet Oncol 15, 1224–1235 (2014)CrossRefPubMed H. Wilke, K. Muro, E. Van Cutsem, S.C. Oh, G. Bodoky, Y. Shimada, S. Hironaka, N. Sugimoto, O. Lipatov, T.Y. Kim, D. Cunningham, P. Rougier, Y. Komatsu, J. Ajani, M. Emig, R. Carlesi, D. Ferry, K. Chandrawansa, J.D. Schwartz, A. Ohtsu, RAINBOW Study Group, Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): A double-blind, randomised phase 3 trial. Lancet Oncol 15, 1224–1235 (2014)CrossRefPubMed

go back to reference S. Kasper, M. Schuler, Targeted therapies in gastroesophageal cancer. Eur J Cancer 50, 1247–1258 (2014)CrossRefPubMed S. Kasper, M. Schuler, Targeted therapies in gastroesophageal cancer. Eur J Cancer 50, 1247–1258 (2014)CrossRefPubMed

go back to reference P. Samson, A.C. Lockhart, Biologic therapy in esophageal and gastric malignancies: Current therapies and future directions. J Gastrointest Oncol 8, 418–429 (2017)CrossRefPubMedPubMedCentral P. Samson, A.C. Lockhart, Biologic therapy in esophageal and gastric malignancies: Current therapies and future directions. J Gastrointest Oncol 8, 418–429 (2017)CrossRefPubMedPubMedCentral

go back to reference J. Tabernero, P.M. Hoff, L. Shen, A. Ohtsu, M.A. Shah, K. Cheng, C. Song, H. Wu, J. Eng-Wong, K. Kim, Y.K. Kang, Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): Final analysis of a double-blind, randomised, placebo-controlled phase 3 study. Lancet Oncol 19, 1372–1384 (2018)CrossRefPubMed J. Tabernero, P.M. Hoff, L. Shen, A. Ohtsu, M.A. Shah, K. Cheng, C. Song, H. Wu, J. Eng-Wong, K. Kim, Y.K. Kang, Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): Final analysis of a double-blind, randomised, placebo-controlled phase 3 study. Lancet Oncol 19, 1372–1384 (2018)CrossRefPubMed

go back to reference P.C. Thuss-Patience, M.A. Shah, A. Ohtsu, E. Van Cutsem, J.A. Ajani, H. Castro, W. Mansoor, H.C. Chung, G. Bodoky, K. Shitara, G.D.L. Phillips, T. van der Horst, M.L. Harle-Yge, B.L. Althaus, Y.K. Kang, Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): An international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol 18, 640–653 (2017)CrossRefPubMed P.C. Thuss-Patience, M.A. Shah, A. Ohtsu, E. Van Cutsem, J.A. Ajani, H. Castro, W. Mansoor, H.C. Chung, G. Bodoky, K. Shitara, G.D.L. Phillips, T. van der Horst, M.L. Harle-Yge, B.L. Althaus, Y.K. Kang, Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): An international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol 18, 640–653 (2017)CrossRefPubMed

go back to reference T. Waddell, I. Chau, D. Cunningham, D. Gonzalez, A.F. Okines, A. Frances, C. Okines, A. Wotherspoon, C. Saffery, G. Middleton, J. Wadsley, D. Ferry, W. Mansoor, T. Crosby, F. Coxon, D. Smith, J. Waters, T. Iveson, S. Falk, S. Slater, C. Peckitt, Y. Barbachano, Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): A randomised, open-label phase 3 trial. Lancet Oncol 14, 481–489 (2013)CrossRefPubMedPubMedCentral T. Waddell, I. Chau, D. Cunningham, D. Gonzalez, A.F. Okines, A. Frances, C. Okines, A. Wotherspoon, C. Saffery, G. Middleton, J. Wadsley, D. Ferry, W. Mansoor, T. Crosby, F. Coxon, D. Smith, J. Waters, T. Iveson, S. Falk, S. Slater, C. Peckitt, Y. Barbachano, Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): A randomised, open-label phase 3 trial. Lancet Oncol 14, 481–489 (2013)CrossRefPubMedPubMedCentral

go back to reference N. Mavaddat, D. Barrowdale, I.L. Andrulis, S.M. Domchek, D. Eccles, H. Nevanlinna, S.J. Ramus, A. Spurdle, M. Robson, M. Sherman, A.M. Mulligan, F.J. Couch, C. Engel, L. McGuffog, S. Healey, O.M. Sinilnikova, M.C. Southey, M.B. Terry, D. Goldgar, F. O'Malley, E.M. John, R. Janavicius, L. Tihomirova, T.V. Hansen, F.C. Nielsen, A. Osorio, A. Stavropoulou, J. Benítez, S. Manoukian, B. Peissel, M. Barile, S. Volorio, B. Pasini, R. Dolcetti, A.L. Putignano, L. Ottini, P. Radice, U. Hamann, M.U. Rashid, F.B. Hogervorst, M. Kriege, R.B. van der Luijt, S. Peock, D. Frost, D.G. Evans, C. Brewer, L. Walker, M.T. Rogers, L.E. Side, C. Houghton, J. Weaver, A.K. Godwin, R.K. Schmutzler, B. Wappenschmidt, A. Meindl, K. Kast, N. Arnold, D. Niederacher, C. Sutter, H. Deissler, D. Gadzicki, S. Preisler-Adams, R. Varon-Mateeva, I. Schönbuchner, H. Gevensleben, D. Stoppa-Lyonnet, M. Belotti, L. Barjhoux, C. Isaacs, B.N. Peshkin, T. Caldes, M. de la Hoya, C. Cañadas, T. Heikkinen, P. Heikkilä, K. Aittomäki, I. Blanco, C. Lazaro, J. Brunet, B.A. Agnarsson, A. Arason, R.B. Barkardottir, M. Dumont, J. Simard, M. Montagna, S. Agata, E. D'Andrea, M. Yan, S. Fox, T.R. Rebbeck, W. Rubinstein, N. Tung, J.E. Garber, X. Wang, Z. Fredericksen, V.S. Pankratz, N.M. Lindor, C. Szabo, K. Offit, R. Sakr, M.M. Gaudet, C.F. Singer, M.K. Tea, C. Rappaport, P.L. Mai, M.H. Greene, A. Sokolenko, E. Imyanitov, A.E. Toland, L. Senter, K. Sweet, M. Thomassen, A.M. Gerdes, T. Kruse, M. Caligo, P. Aretini, J. Rantala, A. von Wachenfeld, K. Henriksson, L. Steele, S.L. Neuhausen, R. Nussbaum, M. Beattie, K. Odunsi, L. Sucheston, S.A. Gayther, K. Nathanson, J. Gross, C. Walsh, B. Karlan, G. Chenevix-Trench, D.F. Easton, A.C. Antoniou, HEBON, EMBRACE, GEMO Study Collaborators, kConFab Investigators, SWE-BRCA Collaborators and Consortium of Investigators of Modifiers of BRCA1/2, Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev 21, 134–147 (2012)CrossRefPubMed N. Mavaddat, D. Barrowdale, I.L. Andrulis, S.M. Domchek, D. Eccles, H. Nevanlinna, S.J. Ramus, A. Spurdle, M. Robson, M. Sherman, A.M. Mulligan, F.J. Couch, C. Engel, L. McGuffog, S. Healey, O.M. Sinilnikova, M.C. Southey, M.B. Terry, D. Goldgar, F. O'Malley, E.M. John, R. Janavicius, L. Tihomirova, T.V. Hansen, F.C. Nielsen, A. Osorio, A. Stavropoulou, J. Benítez, S. Manoukian, B. Peissel, M. Barile, S. Volorio, B. Pasini, R. Dolcetti, A.L. Putignano, L. Ottini, P. Radice, U. Hamann, M.U. Rashid, F.B. Hogervorst, M. Kriege, R.B. van der Luijt, S. Peock, D. Frost, D.G. Evans, C. Brewer, L. Walker, M.T. Rogers, L.E. Side, C. Houghton, J. Weaver, A.K. Godwin, R.K. Schmutzler, B. Wappenschmidt, A. Meindl, K. Kast, N. Arnold, D. Niederacher, C. Sutter, H. Deissler, D. Gadzicki, S. Preisler-Adams, R. Varon-Mateeva, I. Schönbuchner, H. Gevensleben, D. Stoppa-Lyonnet, M. Belotti, L. Barjhoux, C. Isaacs, B.N. Peshkin, T. Caldes, M. de la Hoya, C. Cañadas, T. Heikkinen, P. Heikkilä, K. Aittomäki, I. Blanco, C. Lazaro, J. Brunet, B.A. Agnarsson, A. Arason, R.B. Barkardottir, M. Dumont, J. Simard, M. Montagna, S. Agata, E. D'Andrea, M. Yan, S. Fox, T.R. Rebbeck, W. Rubinstein, N. Tung, J.E. Garber, X. Wang, Z. Fredericksen, V.S. Pankratz, N.M. Lindor, C. Szabo, K. Offit, R. Sakr, M.M. Gaudet, C.F. Singer, M.K. Tea, C. Rappaport, P.L. Mai, M.H. Greene, A. Sokolenko, E. Imyanitov, A.E. Toland, L. Senter, K. Sweet, M. Thomassen, A.M. Gerdes, T. Kruse, M. Caligo, P. Aretini, J. Rantala, A. von Wachenfeld, K. Henriksson, L. Steele, S.L. Neuhausen, R. Nussbaum, M. Beattie, K. Odunsi, L. Sucheston, S.A. Gayther, K. Nathanson, J. Gross, C. Walsh, B. Karlan, G. Chenevix-Trench, D.F. Easton, A.C. Antoniou, HEBON, EMBRACE, GEMO Study Collaborators, kConFab Investigators, SWE-BRCA Collaborators and Consortium of Investigators of Modifiers of BRCA1/2, Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev 21, 134–147 (2012)CrossRefPubMed

go back to reference A.D. Wagner, H.I. Grabsch, M. Mauer, S. Marreaud, C. Caballero, P. Thuss-Patience, L. Mueller, A. Elme, M.H. Moehler, U. Martens, Y.K. Kang, S.Y. Rha, A. Cats, M. Tokunaga, F. Lordick, EORTC-1203-GITCG – The “INNOVATION”-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: A randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group. BMC Cancer 19, 494 (2019)CrossRefPubMedPubMedCentral A.D. Wagner, H.I. Grabsch, M. Mauer, S. Marreaud, C. Caballero, P. Thuss-Patience, L. Mueller, A. Elme, M.H. Moehler, U. Martens, Y.K. Kang, S.Y. Rha, A. Cats, M. Tokunaga, F. Lordick, EORTC-1203-GITCG – The “INNOVATION”-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: A randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group. BMC Cancer 19, 494 (2019)CrossRefPubMedPubMedCentral

go back to reference J.R. Hecht, Y.J. Bang, S.K. Qin, H.C. Chung, J.M. Xu, J.O. Park, K. Jeziorski, Y. Shparyk, P.M. Hoff, A. Sobrero, P. Salman, J. Li, S.A. Protsenko, Z.A. Wainberg, M. Buyse, K. Afenjar, V. Houé, A. Garcia, T. Kaneko, Y. Huang, S. Khan-Wasti, S. Santillana, M.F. Press, D. Slamon, Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiC – A randomized phase III trial. J Clin Oncol 34, 443–451 (2016)CrossRefPubMed J.R. Hecht, Y.J. Bang, S.K. Qin, H.C. Chung, J.M. Xu, J.O. Park, K. Jeziorski, Y. Shparyk, P.M. Hoff, A. Sobrero, P. Salman, J. Li, S.A. Protsenko, Z.A. Wainberg, M. Buyse, K. Afenjar, V. Houé, A. Garcia, T. Kaneko, Y. Huang, S. Khan-Wasti, S. Santillana, M.F. Press, D. Slamon, Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiC – A randomized phase III trial. J Clin Oncol 34, 443–451 (2016)CrossRefPubMed

go back to reference R.J. Kelly, The emerging role of immunotherapy for esophageal cancer. Curr Opin Gastroenterol, 35(4), 337–343 (2019). https://doi.org/10.1097/MOG.0000000000000542 R.J. Kelly, The emerging role of immunotherapy for esophageal cancer. Curr Opin Gastroenterol, 35(4), 337–343 (2019). https://​doi.​org/​10.​1097/​MOG.​0000000000000542​

go back to reference A. Ghahremanloo, A. Soltani, S.M.S. Modaresi, S.I. Hashemy, Recent advances in the clinical development of immune checkpoint blockade therapy. Cell Oncol 42, 609–626 (2019)CrossRef A. Ghahremanloo, A. Soltani, S.M.S. Modaresi, S.I. Hashemy, Recent advances in the clinical development of immune checkpoint blockade therapy. Cell Oncol 42, 609–626 (2019)CrossRef

go back to reference L. Fashoyin-Aje, M. Donoghue, H. Chen, K. He, J. Veeraraghavan, K.B. Goldberg, P. Keegan, A.E. McKee, R. Pazdur, FDA approval summary: Pembrolizumab for recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma expressing PD-L1. Oncologist 24, 103–109 (2019)CrossRefPubMed L. Fashoyin-Aje, M. Donoghue, H. Chen, K. He, J. Veeraraghavan, K.B. Goldberg, P. Keegan, A.E. McKee, R. Pazdur, FDA approval summary: Pembrolizumab for recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma expressing PD-L1. Oncologist 24, 103–109 (2019)CrossRefPubMed

go back to reference T.A. Post, KEYNOTE-181: Pembrolizumab vs chemotherapy in second-line treatment of advanced esophageal cancer. 2019; Available from: https://www.ascopost.com/issues/april-10-2019-supplement-conference-highlights-gugi-2019/keynote-181-in-esophageal-cancer/. Accessed 19 October 2019 T.A. Post, KEYNOTE-181: Pembrolizumab vs chemotherapy in second-line treatment of advanced esophageal cancer. 2019; Available from: https://​www.​ascopost.​com/​issues/​april-10-2019-supplement-conference-highlights-gugi-2019/​keynote-181-in-esophageal-cancer/​. Accessed 19 October 2019

go back to reference FDA. FDA approves pembrolizumab for advanced esophageal squamous cell cancer. July 31; Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-advanced-esophageal-squamous-cell-cancer. Accessed 19 October 2019 FDA. FDA approves pembrolizumab for advanced esophageal squamous cell cancer. July 31; Available from: https://​www.​fda.​gov/​drugs/​resources-information-approved-drugs/​fda-approves-pembrolizumab-advanced-esophageal-squamous-cell-cancer. Accessed 19 October 2019

go back to reference K. Shitara, M. Özgüroğlu, Y.J. Bang, M. Di Bartolomeo, M. Mandalà, M.H. Ryu, L. Fornaro, T. Olesiński, C. Caglevic, H.C. Chung, K. Muro, E. Goekkurt, W. Mansoor, R.S. McDermott, E. Shacham-Shmueli, X. Chen, C. Mayo, S.P. Kang, A. Ohtsu, C.S. Fuchs, KEYNOTE-061 Investigators, Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): A randomised, open-label, controlled, phase 3 trial. Lancet 392, 123–133 (2018)CrossRefPubMed K. Shitara, M. Özgüroğlu, Y.J. Bang, M. Di Bartolomeo, M. Mandalà, M.H. Ryu, L. Fornaro, T. Olesiński, C. Caglevic, H.C. Chung, K. Muro, E. Goekkurt, W. Mansoor, R.S. McDermott, E. Shacham-Shmueli, X. Chen, C. Mayo, S.P. Kang, A. Ohtsu, C.S. Fuchs, KEYNOTE-061 Investigators, Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): A randomised, open-label, controlled, phase 3 trial. Lancet 392, 123–133 (2018)CrossRefPubMed

go back to reference Y.K. Kang, N. Boku, T. Satoh, M.H. Ryu, Y. Chao, K. Kato, H.C. Chung, J.S. Chen, K. Muro, W.K. Kang, K.H. Yeh, T. Yoshikawa, S.C. Oh, L.Y. Bai, T. Tamura, K.W. Lee, Y. Hamamoto, J.G. Kim, K. Chin, D.Y. Oh, K. Minashi, J.Y. Cho, M. Tsuda, L.T. Chen, Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390, 2461–2471 (2017)CrossRefPubMed Y.K. Kang, N. Boku, T. Satoh, M.H. Ryu, Y. Chao, K. Kato, H.C. Chung, J.S. Chen, K. Muro, W.K. Kang, K.H. Yeh, T. Yoshikawa, S.C. Oh, L.Y. Bai, T. Tamura, K.W. Lee, Y. Hamamoto, J.G. Kim, K. Chin, D.Y. Oh, K. Minashi, J.Y. Cho, M. Tsuda, L.T. Chen, Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390, 2461–2471 (2017)CrossRefPubMed

go back to reference N. Boku, M.H. Ryu, K. Kato, H.C. Chung, K. Minashi, K.W. Lee, H. Cho, W.K. Kang, Y. Komatsu, M. Tsuda, K. Yamaguchi, H. Hara, S. Fumita, M. Azuma, L.T. Chen, Y.K. Kang, Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: Interim results of a randomized, phase II trial (ATTRACTION-4). Ann Oncol 30, 250–258 (2019)CrossRefPubMed N. Boku, M.H. Ryu, K. Kato, H.C. Chung, K. Minashi, K.W. Lee, H. Cho, W.K. Kang, Y. Komatsu, M. Tsuda, K. Yamaguchi, H. Hara, S. Fumita, M. Azuma, L.T. Chen, Y.K. Kang, Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: Interim results of a randomized, phase II trial (ATTRACTION-4). Ann Oncol 30, 250–258 (2019)CrossRefPubMed

go back to reference Y.J. Bang, E.Y. Ruiz, E. Van Cutsem, K.W. Lee, L. Wyrwicz, M. Schenker, M. Alsina, M.H. Ryu, H.C. Chung, L. Evesque, S.E. Al-Batran, S.H. Park, M. Lichinitser, N. Boku, M.H. Moehler, J. Hong, H. Xiong, R. Hallwachs, I. Conti, J. Taieb, Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: Primary analysis of JAVELIN Gastric 300. Ann Oncol 29, 2052–2060 (2018)CrossRefPubMedPubMedCentral Y.J. Bang, E.Y. Ruiz, E. Van Cutsem, K.W. Lee, L. Wyrwicz, M. Schenker, M. Alsina, M.H. Ryu, H.C. Chung, L. Evesque, S.E. Al-Batran, S.H. Park, M. Lichinitser, N. Boku, M.H. Moehler, J. Hong, H. Xiong, R. Hallwachs, I. Conti, J. Taieb, Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: Primary analysis of JAVELIN Gastric 300. Ann Oncol 29, 2052–2060 (2018)CrossRefPubMedPubMedCentral

go back to reference Y.J. Bang, J.Y. Cho, Y.H. Kim, J.W. Kim, M. Di Bartolomeo, J.A. Ajani, K. Yamaguchi, A. Balogh, T. Sanchez, M. Moehler, Efficacy of sequential ipilimumab monotherapy versus best supportive care for unresectable locally advanced/metastatic gastric or gastroesophageal junction cancer. Clin Cancer Res 23, 5671–5678 (2017)CrossRefPubMed Y.J. Bang, J.Y. Cho, Y.H. Kim, J.W. Kim, M. Di Bartolomeo, J.A. Ajani, K. Yamaguchi, A. Balogh, T. Sanchez, M. Moehler, Efficacy of sequential ipilimumab monotherapy versus best supportive care for unresectable locally advanced/metastatic gastric or gastroesophageal junction cancer. Clin Cancer Res 23, 5671–5678 (2017)CrossRefPubMed

go back to reference Y.Y. Janjigian, J. Bendell, E. Calvo, J.W. Kim, P.A. Ascierto, P. Sharma, P.A. Ott, K. Peltola, D. Jaeger, J. Evans, F. de Braud, I. Chau, C.T. Harbison, C. Dorange, M. Tschaika, D.T. Le, CheckMate-032 study: Efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer. J Clin Oncol 36, 2836–2844 (2018)CrossRefPubMedPubMedCentral Y.Y. Janjigian, J. Bendell, E. Calvo, J.W. Kim, P.A. Ascierto, P. Sharma, P.A. Ott, K. Peltola, D. Jaeger, J. Evans, F. de Braud, I. Chau, C.T. Harbison, C. Dorange, M. Tschaika, D.T. Le, CheckMate-032 study: Efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer. J Clin Oncol 36, 2836–2844 (2018)CrossRefPubMedPubMedCentral

go back to reference T.A. Post, 2019 ASCO: KEYNOTE-062: Pembrolizumab with or without chemotherapy vs chemotherapy in advanced gastric or GEJ adenocarcinoma; Available from: https://www.ascopost.com/News/60099. Accessed 7 July 2019 T.A. Post, 2019 ASCO: KEYNOTE-062: Pembrolizumab with or without chemotherapy vs chemotherapy in advanced gastric or GEJ adenocarcinoma; Available from: https://​www.​ascopost.​com/​News/​60099. Accessed 7 July 2019

go back to reference Health, N.I.o. An investigational immuno-therapy study of nivolumab or placebo in patients with resected esophageal or gastroesophageal junction cancer (CheckMate 577); Available from: https://clinicaltrials.gov/ct2/show/NCT02743494. Accessed 24 July 2019 Health, N.I.o. An investigational immuno-therapy study of nivolumab or placebo in patients with resected esophageal or gastroesophageal junction cancer (CheckMate 577); Available from: https://​clinicaltrials.​gov/​ct2/​show/​NCT02743494. Accessed 24 July 2019

go back to reference Health, N.I.o. Efficacy study of nivolumab plus ipilimumab or nivolumab plus chemotherapy against chemotherapy in stomach cancer or stomach/esophagus junction cancer (CheckMate649); Available from: https://clinicaltrials.gov/ct2/show/NCT02872116. Accessed 29 July 2019 Health, N.I.o. Efficacy study of nivolumab plus ipilimumab or nivolumab plus chemotherapy against chemotherapy in stomach cancer or stomach/esophagus junction cancer (CheckMate649); Available from: https://​clinicaltrials.​gov/​ct2/​show/​NCT02872116. Accessed 29 July 2019

go back to reference D.N. Ionescu, M.R. Downes, A. Christofides, M.S. Tsao, Harmonization of PD-L1 testing in oncology: A Canadian pathology perspective. Curr Oncol 25, e209–e216 (2018)CrossRefPubMedPubMedCentral D.N. Ionescu, M.R. Downes, A. Christofides, M.S. Tsao, Harmonization of PD-L1 testing in oncology: A Canadian pathology perspective. Curr Oncol 25, e209–e216 (2018)CrossRefPubMedPubMedCentral

go back to reference H. Polioudaki, A. Chantziou, K. Kalyvianaki, P. Malamos, G. Notas, D. Mavroudis, M. Kampa, E. Castanas, P.A. Theodoropoulos, Nuclear localization of PD-L1: Artifact or reality? Cell Oncol 42, 237–242 (2019)CrossRef H. Polioudaki, A. Chantziou, K. Kalyvianaki, P. Malamos, G. Notas, D. Mavroudis, M. Kampa, E. Castanas, P.A. Theodoropoulos, Nuclear localization of PD-L1: Artifact or reality? Cell Oncol 42, 237–242 (2019)CrossRef

go back to reference M. Yi, S. Qin, W. Zhao, S. Yu, Q. Chu, K. Wu, The role of neoantigen in immune checkpoint blockade therapy. Exp Hematol Oncol 7, 28 (2018)CrossRefPubMedPubMedCentral M. Yi, S. Qin, W. Zhao, S. Yu, Q. Chu, K. Wu, The role of neoantigen in immune checkpoint blockade therapy. Exp Hematol Oncol 7, 28 (2018)CrossRefPubMedPubMedCentral

go back to reference C. Luchini, F. Bibeau, M.J.L. Ligtenberg, N. Singh, A. Nottegar, T. Bosse, R. Miller, N. Riaz, J.Y. Douillard, F. Andre, A. Scarpa, ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: A systematic review-based approach. Ann Oncol, doi: 10.1093/annonc/mdz116 (2019) C. Luchini, F. Bibeau, M.J.L. Ligtenberg, N. Singh, A. Nottegar, T. Bosse, R. Miller, N. Riaz, J.Y. Douillard, F. Andre, A. Scarpa, ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: A systematic review-based approach. Ann Oncol, doi: 10.1093/annonc/mdz116 (2019)

go back to reference F. Schettini, I. De Santo, C.G. Rea, P. De Placido, L. Formisano, M. Giuliano, G. Arpino, M. De Laurentiis, F. Puglisi, S. De Placido, L. Del Mastro, CDK 4/6 inhibitors as single agent in advanced solid tumors. Front Oncol 8, 608 (2018)CrossRefPubMedPubMedCentral F. Schettini, I. De Santo, C.G. Rea, P. De Placido, L. Formisano, M. Giuliano, G. Arpino, M. De Laurentiis, F. Puglisi, S. De Placido, L. Del Mastro, CDK 4/6 inhibitors as single agent in advanced solid tumors. Front Oncol 8, 608 (2018)CrossRefPubMedPubMedCentral

go back to reference L. Chen, J. Pan, Dual cyclin-dependent kinase 4/6 inhibition by PD-0332991 induces apoptosis and senescence in oesophageal squamous cell carcinoma cells. Br J Pharmacol 174, 2427–2443 (2017)CrossRefPubMedPubMedCentral L. Chen, J. Pan, Dual cyclin-dependent kinase 4/6 inhibition by PD-0332991 induces apoptosis and senescence in oesophageal squamous cell carcinoma cells. Br J Pharmacol 174, 2427–2443 (2017)CrossRefPubMedPubMedCentral

go back to reference Health, N.I.o. Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC); Available from: https://clinicaltrials.gov/ct2/show/NCT03292250. Accessed 11 October 2017 Health, N.I.o. Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC); Available from: https://​clinicaltrials.​gov/​ct2/​show/​NCT03292250. Accessed 11 October 2017

go back to reference Health, N.I.o. Phase Ib study of TNO155 in combination with spartalizumab or ribociclib in selected malignancies; Available from: https://clinicaltrials.gov/ct2/show/NCT04000529. Accessed 16 July 2019 Health, N.I.o. Phase Ib study of TNO155 in combination with spartalizumab or ribociclib in selected malignancies; Available from: https://​clinicaltrials.​gov/​ct2/​show/​NCT04000529. Accessed 16 July 2019

go back to reference Q. Zhang, J.E. Burdette, J.P. Wang, Integrative network analysis of TCGA data for ovarian cancer. BMC Syst Biol 8, 1338 (2014)CrossRefPubMedPubMedCentral Q. Zhang, J.E. Burdette, J.P. Wang, Integrative network analysis of TCGA data for ovarian cancer. BMC Syst Biol 8, 1338 (2014)CrossRefPubMedPubMedCentral

go back to reference G. Sawada, A. Niida, R. Uchi, H. Hirata, T. Shimamura, Y. Suzuki, Y. Shiraishi, K. Chiba, S. Imoto, Y. Takahashi, T. Iwaya, T. Sudo, T. Hayashi, H. Takai, Y. Kawasaki, T. Matsukawa, H. Eguchi, K. Sugimachi, F. Tanaka, H. Suzuki, K. Yamamoto, H. Ishii, M. Shimizu, H. Yamazaki, M. Yamazaki, Y. Tachimori, Y. Kajiyama, S. Natsugoe, H. Fujita, K. Mafune, Y. Tanaka, D.P. Kelsell, C.A. Scott, S. Tsuji, S. Yachida, T. Shibata, S. Sugano, Y. Doki, T. Akiyama, H. Aburatani, S. Ogawa, S. Miyano, M. Mori, K. Mimori, Genomic landscape of esophageal squamous cell carcinoma in a Japanese population. Gastroenterology 150, 1171–1182 (2016)CrossRefPubMed G. Sawada, A. Niida, R. Uchi, H. Hirata, T. Shimamura, Y. Suzuki, Y. Shiraishi, K. Chiba, S. Imoto, Y. Takahashi, T. Iwaya, T. Sudo, T. Hayashi, H. Takai, Y. Kawasaki, T. Matsukawa, H. Eguchi, K. Sugimachi, F. Tanaka, H. Suzuki, K. Yamamoto, H. Ishii, M. Shimizu, H. Yamazaki, M. Yamazaki, Y. Tachimori, Y. Kajiyama, S. Natsugoe, H. Fujita, K. Mafune, Y. Tanaka, D.P. Kelsell, C.A. Scott, S. Tsuji, S. Yachida, T. Shibata, S. Sugano, Y. Doki, T. Akiyama, H. Aburatani, S. Ogawa, S. Miyano, M. Mori, K. Mimori, Genomic landscape of esophageal squamous cell carcinoma in a Japanese population. Gastroenterology 150, 1171–1182 (2016)CrossRefPubMed

go back to reference N. Wakabayashi, K. Itoh, J. Wakabayashi, H. Motohashi, S. Noda, S. Takahashi, S. Imakado, T. Kotsuji, F. Otsuka, D.R. Roop, T. Harada, J.D. Engel, M. Yamamoto, Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation. Nat Genet 35, 238–245 (2003)CrossRefPubMed N. Wakabayashi, K. Itoh, J. Wakabayashi, H. Motohashi, S. Noda, S. Takahashi, S. Imakado, T. Kotsuji, F. Otsuka, D.R. Roop, T. Harada, J.D. Engel, M. Yamamoto, Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation. Nat Genet 35, 238–245 (2003)CrossRefPubMed

go back to reference Y. Kawasaki, H. Okumura, Y. Uchikado, Y. Kita, K. Sasaki, T. Owaki, S. Ishigami, S. Natsugoe, Nrf2 is useful for predicting the effect of chemoradiation therapy on esophageal squamous cell carcinoma. Ann Surg Oncol 21, 2347–2352 (2014)CrossRefPubMed Y. Kawasaki, H. Okumura, Y. Uchikado, Y. Kita, K. Sasaki, T. Owaki, S. Ishigami, S. Natsugoe, Nrf2 is useful for predicting the effect of chemoradiation therapy on esophageal squamous cell carcinoma. Ann Surg Oncol 21, 2347–2352 (2014)CrossRefPubMed

go back to reference T. Shibata, A. Kokubu, S. Saito, M. Narisawa-Saito, H. Sasaki, K. Aoyagi, Y. Yoshimatsu, Y. Tachimori, R. Kushima, T. Kiyono, M. Yamamoto, NRF2 mutation confers malignant potential and resistance to chemoradiation therapy in advanced esophageal squamous cancer. Neoplasia 13, 864–873 (2011)CrossRefPubMedPubMedCentral T. Shibata, A. Kokubu, S. Saito, M. Narisawa-Saito, H. Sasaki, K. Aoyagi, Y. Yoshimatsu, Y. Tachimori, R. Kushima, T. Kiyono, M. Yamamoto, NRF2 mutation confers malignant potential and resistance to chemoradiation therapy in advanced esophageal squamous cancer. Neoplasia 13, 864–873 (2011)CrossRefPubMedPubMedCentral

go back to reference J. Zhang, Q. Jiao, L. Kong, J. Yu, A. Fang, M. Li, Nrf2 and Keap1 abnormalities in esophageal squamous cell carcinoma and association with the effect of chemoradiotherapy. Thorac Cancer 9, 726–735 (2018)CrossRefPubMedPubMedCentral J. Zhang, Q. Jiao, L. Kong, J. Yu, A. Fang, M. Li, Nrf2 and Keap1 abnormalities in esophageal squamous cell carcinoma and association with the effect of chemoradiotherapy. Thorac Cancer 9, 726–735 (2018)CrossRefPubMedPubMedCentral

go back to reference C. Gorrini, P.S. Baniasadi, I.S. Harris, J. Silvester, S. Inoue, B. Snow, P.A. Joshi, A. Wakeham, S.D. Molyneux, B. Martin, P. Bouwman, D.W. Cescon, A.J. Elia, Z. Winterton-Perks, J. Cruickshank, D. Brenner, A. Tseng, M. Musgrave, H.K. Berman, R. Khokha, J. Jonkers, T.W. Mak, M.L. Gauthier, BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival. J Exp Med 210, 1529–1544 (2013)CrossRefPubMedPubMedCentral C. Gorrini, P.S. Baniasadi, I.S. Harris, J. Silvester, S. Inoue, B. Snow, P.A. Joshi, A. Wakeham, S.D. Molyneux, B. Martin, P. Bouwman, D.W. Cescon, A.J. Elia, Z. Winterton-Perks, J. Cruickshank, D. Brenner, A. Tseng, M. Musgrave, H.K. Berman, R. Khokha, J. Jonkers, T.W. Mak, M.L. Gauthier, BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival. J Exp Med 210, 1529–1544 (2013)CrossRefPubMedPubMedCentral

go back to reference S. Ma, C. Paiboonrungruan, T. Yan, K.P. Williams, M.B. Major, X.L. Chen, Targeted therapy of esophageal squamous cell carcinoma: The NRF2 signaling pathway as target. Ann N Y Acad Sci 1434, 164–172 (2018)CrossRefPubMedPubMedCentral S. Ma, C. Paiboonrungruan, T. Yan, K.P. Williams, M.B. Major, X.L. Chen, Targeted therapy of esophageal squamous cell carcinoma: The NRF2 signaling pathway as target. Ann N Y Acad Sci 1434, 164–172 (2018)CrossRefPubMedPubMedCentral

go back to reference M. Seervi, S. Sumi, A. Chandrasekharan, A.K. Sharma, T.R. SanthoshKumar, Molecular profiling of anastatic cancer cells: Potential role of the nuclear export pathway. Cell Oncol 42, 645–661 (2019)CrossRef M. Seervi, S. Sumi, A. Chandrasekharan, A.K. Sharma, T.R. SanthoshKumar, Molecular profiling of anastatic cancer cells: Potential role of the nuclear export pathway. Cell Oncol 42, 645–661 (2019)CrossRef

go back to reference A. Mizumoto, S. Ohashi, M. Kamada, T. Saito, Y. Nakai, K. Baba, K. Hirohashi, Y. Mitani, O. Kikuchi, J. Matsubara, A. Yamada, T. Takahashi, H. Lee, Y. Okuno, M. Kanai, M. Muto, Combination treatment with highly bioavailable curcumin and NQO1 inhibitor exhibits potent antitumor effects on esophageal squamous cell carcinoma. J Gastroenterol 54, 687-698 (2019) A. Mizumoto, S. Ohashi, M. Kamada, T. Saito, Y. Nakai, K. Baba, K. Hirohashi, Y. Mitani, O. Kikuchi, J. Matsubara, A. Yamada, T. Takahashi, H. Lee, Y. Okuno, M. Kanai, M. Muto, Combination treatment with highly bioavailable curcumin and NQO1 inhibitor exhibits potent antitumor effects on esophageal squamous cell carcinoma. J Gastroenterol 54, 687-698 (2019)

go back to reference T. Yan, H. Cui, Y. Zhou, B. Yang, P. Kong, Y. Zhang, Y. Liu, B. Wang, Y. Cheng, J. Li, S. Guo, E. Xu, H. Liu, C. Cheng, L. Zhang, L. Chen, X. Zhuang, Y. Qian, J. Yang, Y. Ma, H. Li, F. Wang, J. Liu, X. Liu, D. Su, Y. Wang, R. Sun, Y. Li, X. Cheng, Z. Liu, Q. Zhan, Y. Cui, Multi-region sequencing unveils novel actionable targets and spatial heterogeneity in esophageal squamous cell carcinoma. Nat Commun 10, 1670 (2019)CrossRefPubMedPubMedCentral T. Yan, H. Cui, Y. Zhou, B. Yang, P. Kong, Y. Zhang, Y. Liu, B. Wang, Y. Cheng, J. Li, S. Guo, E. Xu, H. Liu, C. Cheng, L. Zhang, L. Chen, X. Zhuang, Y. Qian, J. Yang, Y. Ma, H. Li, F. Wang, J. Liu, X. Liu, D. Su, Y. Wang, R. Sun, Y. Li, X. Cheng, Z. Liu, Q. Zhan, Y. Cui, Multi-region sequencing unveils novel actionable targets and spatial heterogeneity in esophageal squamous cell carcinoma. Nat Commun 10, 1670 (2019)CrossRefPubMedPubMedCentral

go back to reference A. Ashworth, C.J. Lord, Synthetic lethal therapies for cancer: What’s next after PARP inhibitors? Nat Rev Clin Oncol 15, 564–576 (2018)CrossRefPubMed A. Ashworth, C.J. Lord, Synthetic lethal therapies for cancer: What’s next after PARP inhibitors? Nat Rev Clin Oncol 15, 564–576 (2018)CrossRefPubMed

go back to reference J.K. Litton, H.S. Rugo, J. Ettl, S.A. Hurvitz, A. Gonçalves, K.H. Lee, L. Fehrenbacher, R. Yerushalmi, L.A. Mina, M. Martin, H. Roché, Y.H. Im, R.G.W. Quek, D. Markova, I.C. Tudor, A.L. Hannah, W. Eiermann, J.L. Blum, Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med 379, 753–763 (2018)CrossRefPubMed J.K. Litton, H.S. Rugo, J. Ettl, S.A. Hurvitz, A. Gonçalves, K.H. Lee, L. Fehrenbacher, R. Yerushalmi, L.A. Mina, M. Martin, H. Roché, Y.H. Im, R.G.W. Quek, D. Markova, I.C. Tudor, A.L. Hannah, W. Eiermann, J.L. Blum, Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med 379, 753–763 (2018)CrossRefPubMed

go back to reference M. Robson, C. Goessl, S. Domchek, Olaparib for metastatic germline BRCA-mutated breast cancer. N Engl J Med 377, 1792–1793 (2017)CrossRefPubMed M. Robson, C. Goessl, S. Domchek, Olaparib for metastatic germline BRCA-mutated breast cancer. N Engl J Med 377, 1792–1793 (2017)CrossRefPubMed

go back to reference T.A. Post, 2019 ASCO: POLO: Maintenance olaparib in germline BRCA-mutated pancreatic cancer; Available from: https://www.ascopost.com/News/60105. Accessed 16 July 2019 T.A. Post, 2019 ASCO: POLO: Maintenance olaparib in germline BRCA-mutated pancreatic cancer; Available from: https://​www.​ascopost.​com/​News/​60105. Accessed 16 July 2019

go back to reference K. Miyamoto, T. Minegaki, M. Tanahashi, A. Yamamoto, Y. Moriyama, A. Wada, A. Matsumoto, K. Ota, M. Tanaka, U. Masuda, M. Tsujimoto, K. Nishiguchi, Synergistic effects of olaparib and DNA-damaging agents in oesophageal squamous cell carcinoma cell lines. Anticancer Res 39, 1813–1820 (2019)CrossRefPubMed K. Miyamoto, T. Minegaki, M. Tanahashi, A. Yamamoto, Y. Moriyama, A. Wada, A. Matsumoto, K. Ota, M. Tanaka, U. Masuda, M. Tsujimoto, K. Nishiguchi, Synergistic effects of olaparib and DNA-damaging agents in oesophageal squamous cell carcinoma cell lines. Anticancer Res 39, 1813–1820 (2019)CrossRefPubMed

go back to reference Health, N.I.o. Olaparib and ramucirumab in treating patients with metastatic or locally recurrent gastric or gastroesophageal junction cancer that cannot be removed by surgery; Available from: https://clinicaltrials.gov/ct2/show/NCT03008278. Accessed 7 July 2019 Health, N.I.o. Olaparib and ramucirumab in treating patients with metastatic or locally recurrent gastric or gastroesophageal junction cancer that cannot be removed by surgery; Available from: https://​clinicaltrials.​gov/​ct2/​show/​NCT03008278. Accessed 7 July 2019

go back to reference Health, N.I.o. Veliparib, paclitaxel, and carboplatin in treating patients with solid tumors that are metastatic or cannot be removed by surgery and liver or kidney dysfunction; Available from: https://clinicaltrials.gov/ct2/show/NCT01366144. Accessed 4 June 2019 Health, N.I.o. Veliparib, paclitaxel, and carboplatin in treating patients with solid tumors that are metastatic or cannot be removed by surgery and liver or kidney dysfunction; Available from: https://​clinicaltrials.​gov/​ct2/​show/​NCT01366144. Accessed 4 June 2019

go back to reference A. Long, V. Giroux, K.A. Whelan, K.E. Hamilton, M.P. Tétreault, K. Tanaka, J.S. Lee, A.J. Klein-Szanto, H. Nakagawa, A.K. Rustgi, WNT10A promotes an invasive and self-renewing phenotype in esophageal squamous cell carcinoma. Carcinogenesis. 36, 598–606 (2015)CrossRefPubMedPubMedCentral A. Long, V. Giroux, K.A. Whelan, K.E. Hamilton, M.P. Tétreault, K. Tanaka, J.S. Lee, A.J. Klein-Szanto, H. Nakagawa, A.K. Rustgi, WNT10A promotes an invasive and self-renewing phenotype in esophageal squamous cell carcinoma. Carcinogenesis. 36, 598–606 (2015)CrossRefPubMedPubMedCentral

go back to reference S.H. Yang, S.L. Li, Z.M. Dong, Q.C. Kan, Epigenetic inactivation of Wnt inhibitory factor-1 in human esophageal squamous cell carcinoma. Oncol Res 20, 123–130 (2012)CrossRefPubMed S.H. Yang, S.L. Li, Z.M. Dong, Q.C. Kan, Epigenetic inactivation of Wnt inhibitory factor-1 in human esophageal squamous cell carcinoma. Oncol Res 20, 123–130 (2012)CrossRefPubMed

go back to reference Health, N.I.o. A study of LGK974 in patients with malignancies dependent on Wnt ligands; Available from: https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2011-03693&r=1. Accessed 7 July 2019 Health, N.I.o. A study of LGK974 in patients with malignancies dependent on Wnt ligands; Available from: https://​www.​cancer.​gov/​about-cancer/​treatment/​clinical-trials/​search/​v?​id=​NCI-2011-03693&​r=​1. Accessed 7 July 2019

go back to reference A.M. Frankell, S. Jammula, X. Li, G. Contino, S. Killcoyne, S. Abbas, J. Perner, L. Bower, G. Devonshire, E. Ococks, N. Grehan, J. Mok, M. O'Donovan, S. MacRae, M.D. Eldridge, S. Tavaré, R.C. Fitzgerald, Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium, The landscape of selection in 551 esophageal adenocarcinomas defines genomic biomarkers for the clinic. Nat Genet 51, 506–516 (2019)CrossRefPubMedPubMedCentral A.M. Frankell, S. Jammula, X. Li, G. Contino, S. Killcoyne, S. Abbas, J. Perner, L. Bower, G. Devonshire, E. Ococks, N. Grehan, J. Mok, M. O'Donovan, S. MacRae, M.D. Eldridge, S. Tavaré, R.C. Fitzgerald, Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium, The landscape of selection in 551 esophageal adenocarcinomas defines genomic biomarkers for the clinic. Nat Genet 51, 506–516 (2019)CrossRefPubMedPubMedCentral

go back to reference G. Clément, D.M. Jablons, J. Benhattar, Targeting the Wnt signaling pathway to treat Barrett's esophagus. Expert Opin Ther Targets 11, 375–389 (2007)CrossRefPubMed G. Clément, D.M. Jablons, J. Benhattar, Targeting the Wnt signaling pathway to treat Barrett's esophagus. Expert Opin Ther Targets 11, 375–389 (2007)CrossRefPubMed

go back to reference O. Lyros, P. Rafiee, L. Nie, R. Medda, N. Jovanovic, M.F. Otterson, B. Behmaram, I. Gockel, A. Mackinnon, R. Shaker, Wnt/β-catenin signaling activation beyond robust nuclear β-catenin accumulation in nondysplastic Barrett’s esophagus: Regulation via Dickkopf-1. Neoplasia 17, 598–611 (2015)CrossRefPubMedPubMedCentral O. Lyros, P. Rafiee, L. Nie, R. Medda, N. Jovanovic, M.F. Otterson, B. Behmaram, I. Gockel, A. Mackinnon, R. Shaker, Wnt/β-catenin signaling activation beyond robust nuclear β-catenin accumulation in nondysplastic Barrett’s esophagus: Regulation via Dickkopf-1. Neoplasia 17, 598–611 (2015)CrossRefPubMedPubMedCentral

go back to reference L.H. Moyes, H. McEwan, S. Radulescu, J. Pawlikowski, C.G. Lamm, C. Nixon, O.J. Sansom, J.J. Going, G.M. Fullarton, P.D. Adams, Activation of Wnt signalling promotes development of dysplasia in Barrett’s oesophagus. J Pathol 228, 99–112 (2012)PubMed L.H. Moyes, H. McEwan, S. Radulescu, J. Pawlikowski, C.G. Lamm, C. Nixon, O.J. Sansom, J.J. Going, G.M. Fullarton, P.D. Adams, Activation of Wnt signalling promotes development of dysplasia in Barrett’s oesophagus. J Pathol 228, 99–112 (2012)PubMed

go back to reference Y. Kitagawa, T. Uno, T. Oyama, K. Kato, H. Kato, H. Kawakubo, O. Kawamura, M. Kusano, H. Kuwano, H. Takeuchi, Y. Toh, Y. Doki, Y. Naomoto, K. Nemoto, E. Booka, H. Matsubara, T. Miyazaki, M. Muto, A. Yanagisawa, M. Yoshida, Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: Part 1. Esophagus. 16, 1–24 (2019)CrossRefPubMed Y. Kitagawa, T. Uno, T. Oyama, K. Kato, H. Kato, H. Kawakubo, O. Kawamura, M. Kusano, H. Kuwano, H. Takeuchi, Y. Toh, Y. Doki, Y. Naomoto, K. Nemoto, E. Booka, H. Matsubara, T. Miyazaki, M. Muto, A. Yanagisawa, M. Yoshida, Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: Part 1. Esophagus. 16, 1–24 (2019)CrossRefPubMed

go back to reference A.M. Dulak, P. Stojanov, S. Peng, M.S. Lawrence, C. Fox, C. Stewart, S. Bandla, Y. Imamura, S.E. Schumacher, E. Shefler, A. McKenna, S.L. Carter, K. Cibulskis, A. Sivachenko, G. Saksena, D. Voet, A.H. Ramos, D. Auclair, K. Thompson, C. Sougnez, R.C. Onofrio, C. Guiducci, R. Beroukhim, Z. Zhou, L. Lin, J. Lin, R. Reddy, A. Chang, R. Landrenau, A. Pennathur, S. Ogino, J.D. Luketich, T.R. Golub, S.B. Gabriel, E.S. Lander, D.G. Beer, T.E. Godfrey, G. Getz, A.J. Bass, Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet 45, 478–486 (2013)CrossRefPubMedPubMedCentral A.M. Dulak, P. Stojanov, S. Peng, M.S. Lawrence, C. Fox, C. Stewart, S. Bandla, Y. Imamura, S.E. Schumacher, E. Shefler, A. McKenna, S.L. Carter, K. Cibulskis, A. Sivachenko, G. Saksena, D. Voet, A.H. Ramos, D. Auclair, K. Thompson, C. Sougnez, R.C. Onofrio, C. Guiducci, R. Beroukhim, Z. Zhou, L. Lin, J. Lin, R. Reddy, A. Chang, R. Landrenau, A. Pennathur, S. Ogino, J.D. Luketich, T.R. Golub, S.B. Gabriel, E.S. Lander, D.G. Beer, T.E. Godfrey, G. Getz, A.J. Bass, Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet 45, 478–486 (2013)CrossRefPubMedPubMedCentral

go back to reference J.Y. Dai, X. Wang, M.F. Buas, C. Zhang, J. Ma, B. Wei, Y. Li, B. Zhao, T.S. Hyun, X. Chen, K.R. Loeb, R. Odze, L. Yao, X. Sun, S. Self, T.L. Vaughan, Y. Guo, Whole-genome sequencing of esophageal adenocarcinoma in Chinese patients reveals distinct mutational signatures and genomic alterations. Commun Biol 1, 174 (2018)CrossRefPubMedPubMedCentral J.Y. Dai, X. Wang, M.F. Buas, C. Zhang, J. Ma, B. Wei, Y. Li, B. Zhao, T.S. Hyun, X. Chen, K.R. Loeb, R. Odze, L. Yao, X. Sun, S. Self, T.L. Vaughan, Y. Guo, Whole-genome sequencing of esophageal adenocarcinoma in Chinese patients reveals distinct mutational signatures and genomic alterations. Commun Biol 1, 174 (2018)CrossRefPubMedPubMedCentral